Chief Medical Officer · Immunome Inc. (IMNM)

Bob Lechleider

FY2023 is the first fiscal year CompBrief holds for Bob Lechleider as a named executive officer of Immunome; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,915,362

Salary $101,042Stock awards $0Bonus $50,000

2nd of 4 named executive officers at Immunome by FY2023 total.

4 named officers on file for Immunome, FY2023

Bob Lechleider’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunome’s whole pay program stands against its peers

  • Immunome’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Bob Lechleider’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Bob Lechleider compensation by year

Immunome Summary Compensation Table · the one fiscal year held
In US dollars, as Immunome reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$101,042
Bonus$50,000
Stock awards$0
Option awards$2,706,000
Non-equity incentive$58,320
Pension and deferred compensation$0
All other$0
Total$2,915,362

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunome Inc. DEF 14A filed April 26, 2024, accession 0001140361-24-022426, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunome Inc. filed document, accession 0001140361-24-022426. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option400,000—$8.73

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunome Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Immunome’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Clay SiegallPresident, Chief Executive Officer and Chairman of the Board$14,866,831
Bob Lechleider · this pageChief Medical Officer$2,915,362
Jack HigginsChief Scientific Officer$1,840,854
Purnanand SarmaFormer Chief Executive Officer$1,437,295

The full Immunome compensation record

free company brief

This page is one person within Immunome's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunome's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Bob Lechleider's compensation dossier · One-time report. No refunds.